Oppenheimer Starts Summit Therapeutics plc (SMMT) at Outperform
Tweet
Share
E-mailGet Alerts SMMT Hot Sheet
Price: $3.59 -3.75%
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Oppenheimer initiated coverage on Summit Therapeutics plc (NASDAQ: SMMT) with an Outperform rating and a price target of $28.00.
For an analyst ratings summary and ratings history on Summit Therapeutics plc click here. For more ratings news on Summit Therapeutics plc click here.
Shares of Summit Therapeutics plc closed at $11.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- Craig-Hallum Assumes Guardant Health (GH) at Buy, 'We think that GH is undervalued'
- BofA Securities Assumes Altice-USA (ATUS) at Underperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
